. 2024 Feb 20;12(3):286–298. doi: 10.1002/ueg2.12544

TABLE 1.

Baseline sample characteristics and relapse at 3, 6, and 12 months according to demographic and clinical variables.

	N valid	N (%)	S3	S6	S12	p‐value	Unadjusted HR	95% CI
All patients		3016 (100)	0.79	0.71	0.63
Type of gallstone disease	3016
Acute cholangitis		379 (12.6)	0.85	0.79	0.71	<0.001	1
Acute pancreatitis		941 (31.2)	0.77	0.68	0.59		1.55	1.24–1.92
Acute cholecystitis		831 (27.6)	0.79	0.71	0.62		1.38	1.10–1.72
Symptomatic choledocholithiasis		302 (10.0)	0.79	0.75	0.69		1.19	0.89–1.58
Biliary colic		314 (10.4)	0.75	0.64	0.53		1.70	1.31–2.21
Any combination		249 (8.3)	0.81	0.74	0.70		1.26	0.94–1.68
Age (years)	3016	74.6 [59.7–84.1]
≤54		557 (18.5)	0.68	0.60	0.46	<0.001	1
>54		2459 (81.5)	0.81	0.74	0.66		0.53	0.46–0.62
Gender	3016
Women		1538 (51.0)	0.78	0.71	0.61	0.102	1
Men		1478 (49.0)	0.80	0.72	0.64		0.90	0.80–1.02
Charlson comorbidity index	3014	1 [0–2]
Low (0–1)		1825 (60.5)	0.77	0.70	0.62	0.021	1
Medium comorbidity ²		515 (17.1)	0.81	0.72	0.59		0.97	0.83–1.15
High comorbidity ³		676 (22.4)	0.82	0.74	0.68		0.80	0.69–0.94
Diabetes	3014
No		2336 (77.5)	0.79	0.71	0.63	0.680	1
Without complications		589 (19.5)	0.78	0.70	0.62		1.00	0.89–1.21
With complications		91 (3.0)	0.83	0.76	0.63		0.88	0.61–1.27
Chronic renal disease	3014
No		2684 (89.0)	0.78	0.70	0.62	0.003	1
Yes		332 (11.0)	0.86	0.80	0.71		0.67	0.54–0.83
Acute renal dysfunction	3014
No		2821 (93.5)	0.79	0.71	0.63	0.325	1
Yes		193 (6.4)	0.82	0.76	0.65		0.88	0.68–1.14
Acute respiratory dysfunction	3015
No		2959 (98.1)	0.79	0.71	0.63	0.264	1
Yes		56 (1.9)	0.78	0.73	0.59		1.26	0.84–1.89
Acute cardiovascular dysfunction	3016
No		2946 (97.7)	0.79	0.71	0.63	0.833	1
Yes		70 (2.3)	0.77	0.75	0.65		0.96	0.64–1.44
ICU admission	3014
No		2961 (98.2)	0.79	0.71	0.63	0.888	1
Yes		53 (1.8)	0.75	0.71	0.62		1.03	0.66–1.63
Biliary tract	3012
Not dilated		1973 (65.4)	0.77	0.69	0.59	<0.001	1
Dilated		1039 (34.6)	0.82	0.76	0.69		0.76	0.66–0.87
Cholelithiasis	3015
Single cholelithiasis		1504 (49.9)	0.80	0.74	0.66	<0.001	1
Multiple cholelithiasis		1511 (50.1)	0.77	0.69	0.60		1.19	1.05–1.34
Duodenal diverticula ^a	2144
No		1922 (89.6)	0.80	0.73	0.65	0.550	1
Yes		222 (10.4)	0.82	0.75	0.68		0.92	0.73–1.18
Pancreas divisum ^a	2138
No		2107 (98.6)	0.80	0.73	0.65	0.970	1
Yes		31 (1.4)	0.90	0.82	0.69		1.01	0.56–1.84
Sphincterotomy	3016
No		2237 (74.2)	0.77	0.68	0.59	<0.001	1
Yes		779 (25.8)	0.85	0.79	0.74		0.60	0.51–0.70
Cholecystostomy	3013
No		2770 (91.9)	0.79	0.71	0.63	0.080	1
Yes		243 (8.1)	0.80	0.71	0.63		0.97	0.77–1.22
Median follow‐up time (months)		5.3 [2.1–12.4]

Note: N = 3016. Data presented as: n (%); median [25th percentile–75th percentile].

Abbreviations: CI, Confidence Interval; HR, Hazard Ratio; ICU, Intensive care unit.

^{^a}

Duodenal diverticula and pancreas divisum were considered only when computed axial tomography, magnetic resonance imaging, endoscopic ultrasound, or ERCP was performed.